KR102719720B1 - 활성 호산구 식도염을 치료하기 위한 방법 - Google Patents

활성 호산구 식도염을 치료하기 위한 방법 Download PDF

Info

Publication number
KR102719720B1
KR102719720B1 KR1020207006346A KR20207006346A KR102719720B1 KR 102719720 B1 KR102719720 B1 KR 102719720B1 KR 1020207006346 A KR1020207006346 A KR 1020207006346A KR 20207006346 A KR20207006346 A KR 20207006346A KR 102719720 B1 KR102719720 B1 KR 102719720B1
Authority
KR
South Korea
Prior art keywords
patient
eoe
pathway inhibitor
inhibitor
esophageal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207006346A
Other languages
English (en)
Korean (ko)
Other versions
KR20200035442A (ko
Inventor
앨런 라딘
제니퍼 디. 해밀턴
리다 매넌트
Original Assignee
리제너론 파아마슈티컬스, 인크.
사노피 바이오테크놀로지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파아마슈티컬스, 인크., 사노피 바이오테크놀로지 filed Critical 리제너론 파아마슈티컬스, 인크.
Priority to KR1020247034392A priority Critical patent/KR20240152980A/ko
Priority claimed from PCT/US2018/045195 external-priority patent/WO2019028367A1/en
Publication of KR20200035442A publication Critical patent/KR20200035442A/ko
Application granted granted Critical
Publication of KR102719720B1 publication Critical patent/KR102719720B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020207006346A 2017-08-04 2018-08-03 활성 호산구 식도염을 치료하기 위한 방법 Active KR102719720B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247034392A KR20240152980A (ko) 2017-08-04 2018-08-03 활성 호산구 식도염을 치료하기 위한 방법

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762541242P 2017-08-04 2017-08-04
US62/541,242 2017-08-04
US201762561593P 2017-09-21 2017-09-21
US62/561,593 2017-09-21
EP18305252.1 2018-03-08
EP18305252 2018-03-08
PCT/US2018/045195 WO2019028367A1 (en) 2017-08-04 2018-08-03 METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247034392A Division KR20240152980A (ko) 2017-08-04 2018-08-03 활성 호산구 식도염을 치료하기 위한 방법

Publications (2)

Publication Number Publication Date
KR20200035442A KR20200035442A (ko) 2020-04-03
KR102719720B1 true KR102719720B1 (ko) 2024-10-22

Family

ID=63113646

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207006346A Active KR102719720B1 (ko) 2017-08-04 2018-08-03 활성 호산구 식도염을 치료하기 위한 방법
KR1020247034392A Pending KR20240152980A (ko) 2017-08-04 2018-08-03 활성 호산구 식도염을 치료하기 위한 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247034392A Pending KR20240152980A (ko) 2017-08-04 2018-08-03 활성 호산구 식도염을 치료하기 위한 방법

Country Status (9)

Country Link
EP (1) EP3661551A1 (enrdf_load_stackoverflow)
JP (2) JP7417515B2 (enrdf_load_stackoverflow)
KR (2) KR102719720B1 (enrdf_load_stackoverflow)
CN (1) CN111032084A (enrdf_load_stackoverflow)
AU (2) AU2018311981B2 (enrdf_load_stackoverflow)
CA (1) CA3071528A1 (enrdf_load_stackoverflow)
IL (2) IL315556A (enrdf_load_stackoverflow)
MA (1) MA49744A (enrdf_load_stackoverflow)
MX (2) MX2020001305A (enrdf_load_stackoverflow)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3174431A1 (en) * 2020-05-22 2021-11-25 Jennifer D. Hamilton Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
AU2023259287A1 (en) * 2022-04-29 2024-12-12 Akeso Biopharma, Inc Anti-human il-4ra antibody and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI682781B (zh) * 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
KR20160068802A (ko) * 2013-10-23 2016-06-15 제넨테크, 인크. 호산구성 장애를 진단 및 치료하는 방법
KR20170123315A (ko) * 2015-03-11 2017-11-07 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Tslp 결합 단백질

Also Published As

Publication number Publication date
JP2024016237A (ja) 2024-02-06
MX2020001305A (es) 2020-03-09
CN111032084A (zh) 2020-04-17
MA49744A (fr) 2020-06-10
AU2018311981A1 (en) 2020-02-20
CA3071528A1 (en) 2019-02-07
AU2018311981B2 (en) 2024-11-14
KR20240152980A (ko) 2024-10-22
IL272245B2 (en) 2025-02-01
AU2025200955A1 (en) 2025-03-06
RU2020109331A3 (enrdf_load_stackoverflow) 2021-12-28
IL272245A (en) 2020-03-31
JP2020529434A (ja) 2020-10-08
EP3661551A1 (en) 2020-06-10
RU2020109331A (ru) 2021-09-06
IL272245B1 (en) 2024-10-01
MX2024012777A (es) 2024-11-08
KR20200035442A (ko) 2020-04-03
IL315556A (en) 2024-11-01
JP7417515B2 (ja) 2024-01-18

Similar Documents

Publication Publication Date Title
US20210363237A1 (en) Methods for treating active eosinophilic esophagitis
JP6837105B2 (ja) Ｉｌ−４ｒ阻害剤の投与による好酸球性食道炎を治療する方法
KR20230015965A (ko) Il-4r 억제제를 투여함에 의해 호산구성 식도염을 치료하기 위한 방법
JP2024016237A (ja) 活動性好酸球性食道炎を治療する方法
RU2776651C2 (ru) Способы лечения активного эозинофильного эзофагита
HK40029391A (en) Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
HK1218854B (en) Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

P16-X000 Ip right document amended

St.27 status event code: A-5-5-P10-P16-nap-X000

Q16-X000 A copy of ip right certificate issued

St.27 status event code: A-4-4-Q10-Q16-nap-X000